点击蓝字，关注我们 今日上午港股 1. 中国中冶(01618)涨近7%， 机构称矿产资源丰富的建筑企业价值亟待重估。 2. 荣昌生物(09995)再涨超5%， 眼科创新药RC28申报上市，此前已与参天中国达成合作。 3. 来凯医药-B(02105)再涨近6%， 近三个交易日累计涨36%，LAE102 I期临床MAD研究初步结果积极。 4. 优必选(09880)涨超5%， 招商证券国际发表报告指，人形机器人链整机首推优必选，该行上调优必选 目标价。 9. 五矿资源(01208)涨超2%， 拟发行5亿美元于2030年到期的零息可换股债券，用于境外债务再融资。 10. 中国中车(01766)涨超1%， 9月29日，中国中车发布公告，公司及下属企业近三个月合计签订约543.4 亿重大合同。 昨日 美股 1. 阿里巴巴(BABA.US)涨4.65%， 摩根士丹利发表布研报，重申对阿里巴巴"增持"评级，ADR目标价由1 65美元上调至200美元。 2. 理想汽车(LI.US)涨3.57%， 9月27日，理想i6正式于常州智能制造基地开启交付。里昂发研报指，i6车 款销售表现料优于i8。 3. 京东(JD.US)涨0.15 ...

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the “Class Period”), of the important September 30, 2025 lead plaintiff deadline. SO WHAT: If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WH ...

Published September 29, 2025 01:53 PM EDT Morgan Stanley analysts have downgraded Novo Nordisk's stock, pointing in part to falling sales of weight-loss drugs Ozempic and Wegovy. Steve Christo - Corbis / Corbis via Getty Images Key Takeaways An analyst's concerns about demand for Novo Nordisk's blockbuster weight-loss drugs is weighing on the drugmaker's shares to start the week. U.S.-listed shares of Novo Nordisk (NVO) slid in recent trading following a downgrade from Morgan Stanley, which raised concerns ...

LOS ANGELES, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Novo Nordisk A/S, ("Novo" or the "Company") (NYSE: NVO) investors of a class action on behalf of investors that bought securities between May 7, 2025, and July 28, 2025, inclusive (the “Class Period”). Novo investors have until September 30, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or jo ...

We're back on Morning Trade Live. Let's focus on Nova Nordics. The stock was downgraded today at Morgan Stanley.More on that coming up in a bit. The weight loss drug trade has lost some luster. Check out this comparison chart of Nova Nordisk and Eli Liy over the past year.Both stocks are down over the last 12 months. Novo down more than 35% during that time frame. And that is the focus of the morning trade.Joining us now for a closer look at Nova Nordisk is Schwab network host Marley Kaden. Very good mornin ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Novo (NVO) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Novo between May 7, 2025, to July 28, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel ...

U.S. prescriptions for Novo's Ozempic and Wegovy drugs are stagnating, Morgan Stanley analysts said. ...

In the meantime, joining me right now, Diane Kinghal. We've uh talked about Carnival briefly having an up arrow. Diane has the details on the latest report.>> They beat expectations. Look, and you have analysts very bullish on this one coming into the report and it's it did even better than expected. Uh cuz you had some analyst views that were above what consensus was.The street was looking for a buck 32 on adjusted EBS. Uh Carnival reporting a buck 43 revenue expected to top 8 billion. They nailed that as ...

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday.Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1 results.Inventiva reported losses of $(1.84) per share compared to the analyst consensus estimate of loss of 41 cents per share. The company reported quarterly sales of $5.050 million which missed the analyst consensus estimate of $5.310 million.Inventiva shares dipped 5.5% to $5.72 in pre-market trading.Here ar ...

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday.Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1 results.Inventiva reported losses of $(1.84) per share compared to the analyst consensus estimate of loss of 41 cents per share. The company reported quarterly sales of $5.050 million which missed the analyst consensus estimate of $5.310 million.Inventiva shares dipped 5.5% to $5.72 in pre-market trading.Here ar ...